Journal of Tumour Research & Reports

Department of Radiation Oncology, The Third Affiliated Hospital of Harbin Medical University, Haping Road, Nangang District, Harbin, Heilongjiang Province, China

Biography

Dr. Xu has more than 10-year experience in clinical histocompatibility and immunogenetics, and has been directors of ASHI-certified HLA labs in Canada. He was known for his expertise in new lab setup, test utilization and quality improvement. Currently Dr. Xu is the Associate Director of Histocompatibility (Tissue Typing) Lab at UPMC.

Publications

• Research   
  Prognostic Factors in Esophageal Cancer Patients after Definitive Radiotherapy using Simultaneous Integrated Boost-Intensity Modulated Radiotherapy (SIB-IMRT) and Late-Course Boost to Gross Tumor Volume (LCBGTV)
  Author(s): Keita M*, Shuguang Li, Cisse IK, Barry A, Xu Jinrui, Zhao Yan, Song chunyang, Li Juan, Su Jingwei, Xu Qingyong, Traore B and Zhu Shuchai
  
  Objective: To assess pre-treatment factors that can predict the outcome of simultaneous integrated boostintensity-modulated radiotherapy (SIB-IMRT) or Late-course boost to gross tumor volume (LCBGTV) and help to choose treatment strategies appropriate for individual patients. Methods: Data obtained from 174 esophageal cancer (EC) patients, including 51 patients in the SIB-IMRT group and 123 patients in LCBGTV-IMRT group were reviewed between 2008 and 2012. The primary outcome was overall survival (OS) and progression-free survival (PFS) comparison. Results: After the Propensity score matching (PSM) analysis, the 5 year OS rates and median survival in SIBIMRT group and LCBGTV-IMRT group were 52.4%, and 62.2 months and 37.7 %, and 49.6 months, respectively (p=0.491). The 5 year PFS rate was better in the SIB-IMRT group (27,6%; 95% CI :12.2 to 25.8 months) than in the LCBGTV-IMRT group (.. View more»
  

  Abstract PDF